Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Organon & Co.

< Previous 1 2 Next >
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Third Quarter Ended September 30, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Tickers OGN
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
Tickers OGN
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Tickers OGN
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Second Quarter Ended June 30, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Announces Proposed $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the First Quarter Ended March 31, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
From Organon & Co.
Via Business Wire
Tickers OGN
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Third Quarter Ended September 30, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
From Organon & Co.
Via Business Wire
Tickers OGN
First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Bolsters Research & Development Expertise with Two Leadership Appointments
From Organon & Co.
Via Business Wire
Tickers OGN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.